WHO Authorizes Emergency Use of Chinese Coronavirus Vaccine

The World Health Organization (WHO) has authorized the inclusion of the coronavirus vaccine developed by the Chinese pharmaceutical company Sinopharm in its emergency use list, thus becoming the sixth to receive this validation.

This was announced this Friday by the director general of the WHO, Tedros Adhanom Ghebreyesus, at a press conference, where he assured that this vaccine is “safe and effective” and that, therefore, the agency has included it in its list of emergency.

This list serves to evaluate the quality, safety and efficacy of Covid-19 vaccines and, in turn, allows countries to accelerate their own regulatory approval to import and administer the vaccines, which have to be included in this list in order to be able to be administered through the Covax mechanism.

“The addition of this vaccine has the potential to rapidly accelerate access to the Covid-19 vaccine for countries seeking to protect healthcare workers and populations at risk. We urge the manufacturer to participate in the Covax facility and contribute to the objective of a more equitable distribution of vaccines “, said the deputy director general of Access to Health Products of the WHO, Mariângela Simão.

In the case of the Sinopharm vaccine, the WHO assessment has included on-site inspections of the production facility. It is an inactivated vaccine and its “easy requirements” for storage make it “very suitable” for low-resource settings.

It is also the first vaccine to carry a vaccine vial monitor, a small sticker on vaccine vials that changes color as the vaccine is exposed to heat, allowing healthcare workers to know if the vaccine can be use safely.

The WHO Strategic Advisory Group of Experts on Immunization (SAGE) has also completed its review of the vaccine. Based on all available evidence, the WHO recommends the vaccine for adults over 18 years of age, in a two-dose schedule with an interval of three to four weeks. Vaccine efficacy for symptomatic and hospitalized disease was estimated at 79 percent, all age groups combined.

Finally, the WHO advises against an upper age limit for the vaccine because preliminary data and supporting immunogenicity data suggest that it is likely to have a protective effect in older people.

“There is no theoretical reason to believe that the vaccine has a different safety profile in older and younger populations. Therefore, we recommend that countries that use the vaccine in older age groups monitor its safety and efficacy. so that the recommendation is more solid “, has settled the organism.

Leave a Reply

Discover

Sponsor

spot_imgspot_img

Latest

Governor P.Rico will approve project that will privatize the electric corporation

 San Juan, .- The Governor of Puerto Rico, Ricardo Rosselló, said today that he will soon sign the Senate Project 1121, which establishes the...

“America’s presidents,” a portrait of America through its leaders

George Washington posed with a sword, Bill Clinton painted the shadow of Monica Lewinsky's dress and Abraham Lincoln or John F. Kennedy did not...

Bill Gates invests 50 million dollars in the fight against Alzheimer’s

Microsoft co-founder Bill Gates today announced his intention to join the fight against Alzheimer's, which is why he has invested 50 million dollars in...

The Pope warns of the “practical atheism” of those who claim to believe in God but then put “distances” with others

Pope Francis has warned of the "practical atheism" of those who claim to believe in God, but then put "distance" with others while stressing...

The Tribeca Film Festival kicks off with a love letter to the Apollo Theater

New York, - With a love letter to the historic Apollo Theater, a whole institution of black music located in the New York neighborhood...
%d bloggers like this: